Rua Bioscience Limited — Earnings Release 2024

Aug 29, 2024

Results Announcement

==> picture [133 x 77] intentionally omitted <==

==> picture [4 x 16] intentionally omitted <==

==> picture [5 x 17] intentionally omitted <==

Results for announcement to the market	Results for announcement to the market	Results for announcement to the market	Results for announcement to the market
Name of issuer	Rua Bioscience Limited
Reporting Period	12 months to 30 June 2024
Previous Reporting Period	12 months to 30 June 2023
Currency	NZD
	Amount (000s)	Percentage change
Revenue from continuingoperations	$322	-53%
Total Revenue	$322	-53%
Net profit/(loss) from continuingoperations	($13,725)	-130%
Total net profit/(loss)	($13,725)	-130%
Interim/Final Dividend
Amount per Quoted Equity Security	No dividend has been declared
Imputed amount per Quoted EquitySecurity	N/A
Record Date	N/A
Dividend Payment Date	N/A
	Current period		Prior comparable period
Net tangible assets per QuotedEquity Security	$0.03		$0.06
A brief explanation of any of thefigures above necessary to enablethe figures to be understood	Rua’s FY24 performance is set out in the company’s Investor Presentationattached to this announcement, which provides detail and explanatorycomment on: operating and financial performance of the business and variousother relevant aspects of the financial performance for the year ended 30 June2024. No dividend has been declared for this period.
Authority for this announcement
Name of person authorised to makethis announcement	Paul Naske, Chief Executive Officer
Contact person for thisannouncement	Paul Naske, Chief Executive Officer
Contact phone number	+64 21 445 154
Contact email address	paul.naske@ruabio.com
Date of release through MAP	29/08/2024

Audited financial statements accompany this announcement.

PO Box 1387, Gisborne 4040, Aotearoa New Zealand | 0800 RUABIO | www.ruabio.com